Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | BRD4 | O60885 | 8/20 | 0.53 |
| ▸ | NT5C2 | P49902 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | BRAF | P15056 | 2/20 | 0.48 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | NT5E | P21589 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TOP2A | P11388 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29638098 | 1.00 | NPC1 (0.56) | NPC1RAB9ABRD4NT5C2CYP3A4 | |
| SCHEMBL38663949 | 0.89 | BRD4 (0.58) | NPC1RAB9ABRD4NT5C2CYP3A4 | |
| SCHEMBL545883 | 0.82 | NPC1 (0.38) | NPC1RAB9ABRD4NT5C2CYP3A4 | |
| SCHEMBL28669706 | 0.81 | NPC1 (0.63) | NPC1RAB9ABRD4NT5C2CYP3A4 | |
| SCHEMBL17372612 | 0.81 | NPC1 (0.35) | NPC1RAB9ABRD4CYP3A4HDAC1 | |
| SCHEMBL30928300 | 0.80 | HDAC1 (0.38) | NPC1RAB9ABRD4NT5C2HDAC1 | |
| SCHEMBL28828155 | 0.79 | BRD4 (0.59) | NPC1RAB9ABRD4NT5C2CYP3A4 | |
| SCHEMBL5437612 | 0.78 | BRD4 (0.62) | NPC1RAB9ABRD4NT5C2CYP3A4 | |
| SCHEMBL23748507 | 0.77 | NPC1 (0.55) | NPC1RAB9ABRD4NT5C2BRAF | |
| SCHEMBL17372559 | 0.77 | NPC1 (0.55) | NPC1RAB9ABRD4NT5C2BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 340 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111430-A1 | CHEMICAL MODIFICATIONS IN mRNA POLY(A) TAIL | PRIME MEDICINE, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| WO-2025111452-A2 | CHEMICAL MODIFICATIONS IN PEgRNA and ngRNAs | PRIME MEDICINE, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| WO-2025043082-A2 | COMPOSITIONS AND METHODS TO IMPROVE RNA PROPERTIES USING BASE, PHOSPHODIESTER LINKAGE, SUGAR BACKBONE, AND CAP MODIFICATIONS | THE BROAD INSTITUTE, INC. (US) | 2025-02-27 | — | — | WO | claimed |
| WO-2025038970-A1 | MODIFIED OLIGONUCLEOTIDES CONTAINING MULTIPLE OLIGONUCLEOTIDES | ADARX PHARMACEUTICALS, INC. (US) | 2025-02-20 | — | — | WO | claimed |
| WO-2025038971-A1 | OLIGONUCLEOTIDES CONTAINING A LIGAND AT A NUCLEOBASE, 2' POSITION, OR 3' POSITION | ADARX PHARMACEUTICALS, INC. (US) | 2025-02-20 | — | — | WO | claimed |
| WO-2025038960-A1 | OLIGONUCLEOTIDES CONTAINING A LIGAND AT AN INTERNAL POSITION | ADARX PHARMACEUTICALS, INC. (US) | 2025-02-20 | — | — | WO | claimed |
| WO-2025038963-A1 | OLIGONUCLEOTIDES CONTAINING MULTIPLE LIGANDS AND/OR LIPIDS | ADARX PHARMACEUTICALS, INC. (US) | 2025-02-20 | — | — | WO | claimed |
| EP-4466074-A1 | POLY-TAILED AND POLY-CAPPED MRNA AND USES THEREOF | The Broad Institute Inc. (US) | 2024-11-27 | — | — | EP | claimed |
| US-20240277872-A1 | MODIFIED MRNA, MODIFIED NON-CODING RNA, AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2024-08-22 | — | — | US | claimed |
| US-20240229109-A1 | METHODS FOR IDENTIFICATION AND RATIO DETERMINATION OF RNA SPECIES IN MULTIVALENT RNA COMPOSITIONS | MODERNATX, INC. (US) | 2024-07-11 | — | — | US | claimed |
| EP-4337331-A1 | MODIFIED MRNA, MODIFIED NON-CODING RNA, AND USES THEREOF | The Broad Institute Inc. (US) | 2024-03-20 | — | — | EP | claimed |
| EP-4314332-A2 | METHODS FOR IDENTIFICATION AND RATIO DETERMINATION OF RNA SPECIES IN MULTIVALENT RNA COMPOSITIONS | ModernaTX, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| WO-2023141474-A9 | POLY-TAILED AND POLY-CAPPED MRNA AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2023-10-26 | — | — | WO | claimed |
| WO-2023141474-A1 | POLY-TAILED AND POLY-CAPPED MRNA AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2023-07-27 | — | — | WO | claimed |
| WO-2022241045-A1 | MODIFIED MRNA, MODIFIED NON-CODING RNA, AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2022-11-17 | — | — | WO | claimed |
| WO-2022212711-A2 | METHODS FOR IDENTIFICATION AND RATIO DETERMINATION OF RNA SPECIES IN MULTIVALENT RNA COMPOSITIONS | MODERNATX, INC. (US) | 2022-10-06 | — | — | WO | claimed |
| WO-2026106695-A1 | TARGETED NANOPARTICLES ENCAPSULATING WATER-SOLUBLE THERAPEUTICS, METHODS OF PRODUCTION, AND USE | OPTIMEOS LIFE SCIENCES, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026098357-A1 | FREEZE-DRIED NUCLEIC ACID-LOADED LIPID NANOPARTICLE AND RECONSTITUTION METHOD THEREOF | KUDO BIOTECHNOLOGY, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| WO-2015196130-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015196118-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240277872-A1 | MODIFIED MRNA, MODIFIED NON-CODING RNA, AND USES THEREOF | NSUN3, NSUN2, RNGTT | NPC1 3287/4885RAB9A 2620/4885BRD4 2839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.